CN112442095A - Refining method of vitamin B12 and application of obtained product - Google Patents

Refining method of vitamin B12 and application of obtained product Download PDF

Info

Publication number
CN112442095A
CN112442095A CN202011400144.8A CN202011400144A CN112442095A CN 112442095 A CN112442095 A CN 112442095A CN 202011400144 A CN202011400144 A CN 202011400144A CN 112442095 A CN112442095 A CN 112442095A
Authority
CN
China
Prior art keywords
vitamin
tumor cells
refining
refining method
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202011400144.8A
Other languages
Chinese (zh)
Other versions
CN112442095B (en
Inventor
张红夺
金峰
金涛
王雯
金成福
李仙洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Kedai Bio Tech Co ltd
Original Assignee
Nanjing Astor Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Astor Pharmaceutical Technology Co ltd filed Critical Nanjing Astor Pharmaceutical Technology Co ltd
Priority to CN202011400144.8A priority Critical patent/CN112442095B/en
Publication of CN112442095A publication Critical patent/CN112442095A/en
Application granted granted Critical
Publication of CN112442095B publication Critical patent/CN112442095B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a refining method of vitamin B12. The invention relates to a refining method of vitamin B12, which comprises the following steps: mixing the vitamin B12 crude product with an organic solvent, cooling to 0-5 ℃, adding a reducing agent, stirring at room temperature for 1-2 hours, filtering, and drying at 40-60 ℃ in vacuum to obtain a refined vitamin B12 pure product, wherein the purity of the vitamin B12 pure product is more than 99%. The vitamin B12 is creatively used as the BNCT type medicine auxiliary medicine, the enrichment effect of the BNCT type medicine in tumor cells is more obvious through synergistic use, and meanwhile, the vitamin B12 has the effects of protecting cells, improving the immunity of the organism and the like.

Description

Refining method of vitamin B12 and application of obtained product
Technical Field
The invention relates to the technical field of chemistry, in particular to a refining method of vitamin B12 and application of a product obtained by the method.
Background
Vitamin B12, also called cobalamin, is a polycyclic compound containing 3-valent cobalt, and 4 reduced pyrrole rings are linked together to become 1 corrin macrocycle (similar to porphyrin), which is the only vitamin containing metal elements. The vitamin B12 is red crystal powder, has no smell and taste, is slightly soluble in water and ethanol, is most stable under the condition of pH 4.5-5.0 and weak acid, and can be decomposed in strong acid (pH <2) or alkaline solution to a certain extent when being heated. Higher animals and plants cannot produce vitamin B12, and vitamin B12 in nature is synthesized by microorganisms. Vitamin B12 is the only vitamin that needs the help of intestinal secretions (endogenous factors) to be absorbed, and is involved in the production of bone marrow red blood cells, prevention of pernicious anemia, and prevention of damage to the cerebral nerves. The physiological effects include the following: b12 is known to be a coenzyme for several mutases, such as methylaspartic mutase, which catalyzes the conversion of Glu to methyl Asp, methylmalonyl CoA mutase, which catalyzes the conversion of methylmalonyl CoA to succinyl CoA. The B12 coenzyme is also involved in the transfer of methyl and other one-carbon units. B12 is mainly found in meat, soybean in plant and some herbs also contain B12, intestinal bacteria can be synthesized, so the B12 is not lack in general, but B12 is a vitamin which is easy to be lacked by digestive tract disease patients and is an essential element which is indispensable for erythropoiesis, and if the B12 is seriously lacked, pernicious anemia is caused. Vitamin B12 is widely present in animal food. And the form cannot be absorbed by human body. In addition, vitamin B12 is also the only vitamin containing essential minerals, and is red due to cobalt, also known as red vitamin, which is a few colored vitamins. Although vitamin B12 belongs to B group vitamin, it can be stored in liver, and its deficiency symptoms can only appear after more than half a year. The vitamin B12 is required in a very small amount and is not deficient as long as the diet is normal. A small number of people with poor absorption need special attention.
Boron Neutron Capture Therapy (Boron Neutron Capture Therapy) BNCT (BNCT for short) is applied to thermal Neutron irradiation to target Boron gathered at tumor or cancer parts, and generates heavy particle alpha particles (helium nuclei) and high-energy Li nuclei after capturing neutrons, thereby selectively killing tumor and cancer cells.
The vitamin B12 as BNCT type drug adjuvant is not reported in the literature, and is a great breakthrough if reasonable use can be realized. Meanwhile, since crude vitamin B12 has many impurities due to a complicated preparation process and cannot be directly applied, a refining method thereof needs to be studied.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a refining method of vitamin B12, and the pure vitamin B12 obtained by the method can be used as BNCT type medicine auxiliary medicines. The effect of high concentration enrichment of boron ions in tumor cells is enhanced.
The technical scheme is as follows: the invention relates to a refining method of vitamin B12, which comprises the following steps: mixing the vitamin B12 crude product with an organic solvent, cooling to 0-5 ℃, adding a reducing agent, stirring at room temperature for 1-2 hours, filtering, and drying at 40-60 ℃ in vacuum to obtain a refined vitamin B12 pure product, wherein the purity of the vitamin B12 pure product is more than 99%.
Specifically, the organic solvent is: methanol and ethanol.
Specifically, the reducing agent is sodium cyanoborohydride.
Specifically, the addition amount of the reducing agent is 10-15% of the mass of the crude vitamin B12.
The purity of the vitamin B12 pure product obtained by the method is within 99.4-99.7%.
Furthermore, the invention also provides an application of the refining method of vitamin B12, and the pure vitamin B12 product obtained by the method in claim 1 and an o-carborane derivative are subjected to synergistic action to increase the selectivity of tumor cells on boron ions, so that the effect of high-concentration enrichment of the boron ions in the tumor cells is enhanced.
Specifically, the structure of the o-carborane derivative is as follows:
Figure BDA0002812019680000031
specifically, the mass ratio of the pure vitamin B12 to the o-carborane derivative is as follows: 1: 10-12. Preferably 1: 10.
Further, the resulting application may ultimately inhibit tumor cells, or kill tumor cells by irradiation with external atomic energy.
Has the advantages that: the vitamin B12 is creatively used as the BNCT type medicine auxiliary medicine, the enrichment effect of the BNCT type medicine in tumor cells is more obvious through synergistic use, and meanwhile, the vitamin B12 has the effects of protecting cells, improving the immunity of the organism and the like.
Drawings
FIG. 1 is a liquid chromatogram of vitamin B12 crude product
FIG. 2 is a liquid chromatogram of pure vitamin B12 obtained in example 1
FIG. 3 is a liquid chromatogram of pure vitamin B12 obtained in example 2
FIG. 4 is a liquid chromatogram of a blank experiment of vitamin B12 obtained in example 3
Detailed Description
The following examples illustrate the invention in more detail, but the scope of the invention is not limited to the examples.
Example 1
Adding 10 g of crude vitamin B12 (with the content of 96.512%) and 100 g of methanol into a 500 ml round-bottom flask, cooling to 0-5 ℃, adding 1 g of sodium cyanoborohydride for 3 times, stirring at room temperature for 1 hour, filtering, and vacuum-drying at 50 ℃ for 12 hours to obtain a pure vitamin B12 with the yield of 8.6 g being 86%; the purity is greater than 99.674%. The chromatogram is shown in FIG. 2, and the data are shown in the following table
Checker A214nm
Peak# Ret.Time Area Height Area% Conc. Unit
1 3.600 44751 5051 0.180 0.180
2 3.876 3081 414 0.019 0.019
3 4.226 15886874 1606650 99.674 99.674
4 6.080 4291 385 0.027 0.027
5 6.863 3605 287 0.023 0.023
6 7.361 1221 95 0.008 0.008
7 19.341 10634 434 0.067 0.067
8 22.669 10720 467 0.067 0.067
9 22.875 3862 352 0.024 0.024
10 24.247 2392 182 0.015 0.015
11 24.492 1081 159 0.007 0.007
Total of 15972511 1614477 100.000
Example 2
Adding 10 g of crude vitamin B12 (with the content of 96.512%) and 100 g of ethanol into a 500 ml round-bottom flask, cooling to 0-5 ℃, adding 1 g of sodium cyanoborohydride for 3 times, stirring at room temperature for 2 hours, filtering, and vacuum-drying at 50 ℃ for 12 hours to obtain a pure vitamin B12 with the yield of 8.9 g being 89%; the purity is greater than 99.464%. The chromatogram is shown in FIG. 3, and the data are shown in the following table
Detector A214nm
Peak# Ret.Time Area Height Area% Conc. Unit
1 3.600 44751 5051 0.280 0.280
2 3.876 3081 414 0.019 0.019
3 4.226 15886874 1606650 99.464 99.464
4 6.080 4291 385 0.027 0.027
5 6.863 3605 287 0.023 0.023
6 7.361 1221 95 0.008 0.008
7 19.341 10634 434 0.067 0.067
8 22.669 10720 467 0.067 0.067
9 22.875 3862 352 0.024 0.024
10 24.247 2392 182 0.015 0.015
11 24.492 1081 159 0.007 0.007
Total of 15972511 1614477 100.000
Example 3
(blank experiment without adding sodium cyanoborohydride) 10 g of crude vitamin B12 (content 96.512%) and 100 g of ethanol are added into a 500 ml round-bottom flask, the temperature is reduced to 0-5 ℃, the mixture is stirred for 2 hours at room temperature, filtered and dried in vacuum at 50 ℃ for 12 hours to obtain a pure vitamin B12 with 9.9 g and 99% yield; the purity was 96.912%. The chromatogram is shown in FIG. 4, and the data are shown in the following table
Detector A214nm
Peak# Ret.Time Area Height Area% Conc. Unit
1 2.978 71287 5899 0.313 0.313
2 3.607 202610 22760 1.431 1.431
3 4.228 13668896 1410020 96.912 96.912
4 7.237 5171 332 0.037 0.037
5 16.184 148841 2561 1.051 1.051
6 19.283 7422 285 0.052 0.052
7 22.698 43870 1228 0.310 0.310
8 24.200 14838 452 0.105 0.105
Total of 14162934 1443537 100.000
Example 4
The results of the in vitro cell activity test of the o-carborane derivatives of the invention and the vitamin B12.
The structure of the o-carborane derivative is as follows:
Figure BDA0002812019680000061
the determination of the related performance indexes of the compound is a common method in the field.
1. Determination of IC50
At different sample concentrations, after 48h of administration, the compound was tested for growth inhibition on colon tumor cells CT26 by the general MTT method, and finally IC50 was calculated so that the drug concentration required to inhibit cell survival was determined from half the lethal dose, and the results represent the average ±. .
MTT is tetramethyl azoazolium salt, which is a yellow dye capable of accepting hydrogen ions. Succinate dehydrogenase (succinate dehydrogenase) and cytochrome c (cytochromec) in mitochondria of living cells can crystallize blue-purple formazan (formazan) to precipitate MTT, and dead cells do not have this function. After the formed formazan crystals were dissolved in dimethyl sulfoxide (DMSO), the amount of formazan formed was monitored by measuring the absorbance of the solution at 490nM or 570nM using an enzyme-linked immunosorbent assay. Since formazan crystals are produced in an amount proportional to the number of living cells, the effect of the drug on the cell viability can be detected. The method is widely used for screening and testing the antitumor drugs due to the characteristics of high sensitivity, economy and the like.
The specific experimental method is as follows: various cells are prepared into 5 multiplied by 10 after centrifugation3Adding 100 mu L of cell suspension into each well of a 96-well plate, sucking out original culture solution after culturing for 24h conventionally, adding 200 mu L of prepared compound I, II or Boron Phenylalanine (BPA) samples, 5 concentrations of compound I and vitamin B12 and compound II and vitamin B12, wherein the final concentration of each sample is 0.137 mu M, 0.046 mu M, 1.235 mu M, 0.412 mu M and 3.704 mu M, each concentration is 4 multiple wells, wells around the 96-well plate are sealed by PBS, a negative control group and a blank control group are reserved, 20 mu L of MTT solution is added into each well after the compound acts for 72h, culturing is continued for 4h, carefully sucking away the culture medium in the wells, adding 150 mu L of DMSO, shaking for 10min, measuring the OD value of each well at 490nM of a microplate reader, and calculating the inhibition rate of the samples at different concentrations according to the following formula: inhibition rate (control well OD value-dosing well OD value)/control well OD value × 100%. Finally, the IC50 value of the sample was calculated using the relevant software.
The operation method comprises the following steps:
(1) colon tumor CT26 cell (5X 10)5Individual cells) were cultured aerobically and anaerobically in 96-well plates. Under the aerobic culture condition of 36.5-37 ℃, sterile deionized oxygen is provided, and the oxygen supply speed is per minute/0.3 cm2And sufficient time was given at 12 hours. The anaerobic culture condition is 36.5-37 ℃, the condition of a sterile anaerobic sealed drying oven is adopted, and the sufficient time is 12 hours.
(2) The o-carborane compounds I, II, compound I with vitamin B12, compound II with vitamin B12 and Borophenylalanine (BPA) were treated sequentially (3mM to 1mM) for 72 hours.
(3) Sequentially adding 3- (4, 5-dimethylthiazole-2) -2, 5-diphenyl tetrazole bromine salt solution, and culturing for 4 hours.
(4) Shaking was performed after dilution with 150. mu.L of dimethyl sulfoxide.
(5) The protein content is measured by an enzyme linked immunosorbent assay device at 595 nm.
2. Boron absorption
P-35 cells (5X 10)3Cells) were treated in the presence of compounds I, II and Borophenylalanine (BPA) (unified boron concentration of 10.8ppm) for 3 hours. Washing with 3 drops of phosphate buffer salt solution for three times;
(4) perchloric/peroxy acids were analyzed.
(5) Aerobic and anaerobic cultures were performed at 70 ℃. Under the aerobic culture condition of 36.5-37 ℃, sterile deionized oxygen is provided, and the oxygen supply speed is per minute/0.3 cm2And sufficient time was given at 12 hours. The anaerobic culture condition is 36.5-37 ℃, the condition of a sterile anaerobic sealed drying oven is adopted, and the sufficient time is 12 hours.
(6) Plasma emission spectrometry testing.
The operation method comprises the following steps:
(1) colon tumor CT26 cell (5X 10)5Individual cells) were cultured aerobically and anaerobically in p-35 cell dishes. Under the aerobic culture condition of 36.5-37 ℃, sterile deionized oxygen is provided, and the oxygen supply speed is per minute/0.3 cm2And sufficient time was given at 12 hours. The anaerobic culture condition is 36.5-37 ℃, the condition of a sterile anaerobic sealed drying oven is adopted, and the sufficient time is 12 hours.
(2) The o-carborane derivatives I, II, compound I and vitamin B12, and compound II and vitamin B12 were treated sequentially (boron concentration 10.8ppm) for 3 hours.
(3) And washed three more times with 3 drops of phosphate buffered saline.
(4) The activity assay was then performed with perchloric/peroxyacids.
(5) Aerobic and anaerobic cultures were performed at 70 ℃. Under the aerobic culture condition of 36.5-37 ℃, sterile deionized oxygen is provided, and the oxygen supply speed is per minute/0.3 cm2And sufficient time was given at 12 hours. The anaerobic culture condition is 36.5-37 ℃, the condition of a sterile anaerobic sealed drying oven is adopted, and the sufficient time is 12 hours.
(6) Plasma emission spectrometry testing.
The following table: IC50 and boron accumulation concentration tables for different compounds
Figure BDA0002812019680000091
As a result, the IC50 activities of BPA were 6.43X 10, respectively-5(+/-0.22) and the aggregation concentration of boron is 0.083 +/-0.012 ppm, while the designed compounds I and II reach the high aggregation concentration which is 8-10 times that of BPA, and the IC50 activity of the compound I is 1.10 multiplied by 10 respectively-5(± 0.22); the boron concentration is 0.682 +/-0.42 ppm respectively; the IC50 activities of the compound II were 1.89X 10-5(± 0.73); the boron concentration was 0.754. + -. 0.43ppm, respectively, and the aggregation effect of the original design was sufficiently obtained. However, the IC50 activity of Compound I after addition of vitamin B12 was 1.21X 10, respectively-5(± 0.13); the boron concentration is 0.814 plus or minus 0.21ppm respectively; the IC50 activities of the compound II were 1.94X 10-5(± 0.58); the boron concentration is 0.912 +/-0.32 ppm, the inhibition activity of tumor cells and tumor cells becomes more prominent, and the inhibition effect is increased by 1-3 times. The self structure of the borane medicament has certain inhibitory activity through in vitro experiments, the concentration of boron is increased in cells by additionally introducing borane, and boron ions are easier to gather in tumor cells to reach the high boron gathering effect by the novel structure. When high boron is accumulated in tumor cells, irradiation is carried out by external atomic energy to generate heavy particles of alpha particles (helium nuclei) andhigh-energy Li nucleus to kill tumor cell selectively.
The above description is only a preferred embodiment of the present application and is not intended to limit the present application.

Claims (8)

1. A refining method of vitamin B12 is characterized by mixing a vitamin B12 crude product with an organic solvent, cooling to 0-5 ℃, adding a reducing agent, stirring at room temperature for 1-2 hours, filtering, and drying at 40-60 ℃ in vacuum to obtain a refined vitamin B12 pure product, wherein the purity of the vitamin B12 pure product is more than 99%.
2. The method for refining vitamin B12, according to claim 1, wherein the organic solvent is: methanol and ethanol.
3. The method for refining vitamin B12, according to claim 1, wherein the reducing agent is sodium cyanoborohydride.
4. The refining method of vitamin B12 of claim 1, wherein the addition amount of the reducing agent is 10% -15% of the weight of crude vitamin B12.
5. The use of the refining method of vitamin B12 as claimed in claim 1, wherein the vitamin B12 pure product obtained by the method as claimed in claim 1 synergistically acts with the o-carborane derivative to increase the selectivity of tumor cells to boron ions, thereby enhancing the effect of enriching the boron ions in the tumor cells at a high concentration.
6. The use of the process for purifying vitamin B12 according to claim 5, wherein the orthocarborane derivative has the following structure:
Figure FDA0002812019670000011
7. the use of the refining method of vitamin B12 according to claim 5, wherein the mass ratio of the pure vitamin B12 to the o-carborane derivative is as follows: 1: 10-12.
8. The use of vitamin B12 in accordance with claim 5, wherein the vitamin B12 is used for inhibiting tumor cells or killing tumor cells by external atomic energy irradiation.
CN202011400144.8A 2020-12-01 2020-12-01 Refining method of vitamin B12 and application of obtained product Active CN112442095B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011400144.8A CN112442095B (en) 2020-12-01 2020-12-01 Refining method of vitamin B12 and application of obtained product

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011400144.8A CN112442095B (en) 2020-12-01 2020-12-01 Refining method of vitamin B12 and application of obtained product

Publications (2)

Publication Number Publication Date
CN112442095A true CN112442095A (en) 2021-03-05
CN112442095B CN112442095B (en) 2022-07-22

Family

ID=74739548

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011400144.8A Active CN112442095B (en) 2020-12-01 2020-12-01 Refining method of vitamin B12 and application of obtained product

Country Status (1)

Country Link
CN (1) CN112442095B (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000045857A2 (en) * 1999-02-01 2000-08-10 Schering Aktiengesellschaft Metal macrocycles for two-step forms of radiotherapy
WO2000062808A2 (en) * 1999-04-16 2000-10-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as antitumor agents
CN1524086A (en) * 2001-06-05 2004-08-25 ������������ʽ���� Process for producing methylcobalamin
CN1620289A (en) * 2001-06-06 2005-05-25 布鲁克黑文科学联合会 Novel metalloporphyrins and their uses as radiosensitizers for radiation therapy
CN101268085A (en) * 2005-08-19 2008-09-17 海默尔凯普股份公司 Boron compounds useful in BNCT
CN102977173A (en) * 2012-12-13 2013-03-20 上海华震科技有限公司 Purifying process of high-purity vitamin B12
CN106279231A (en) * 2016-08-24 2017-01-04 南京江原安迪科正电子研究发展有限公司 Boron-containing compound for BNCT and its production and use
MX2016006530A (en) * 2016-05-19 2017-11-20 Interquim S A De C V Process for transforming methylcobalamin into cyanocobalamin.
CN109928999A (en) * 2019-04-08 2019-06-25 童永彭 The preparation method and application of boron-containing compound, pharmaceutical composition and boron-containing compound
CN111217846A (en) * 2020-04-20 2020-06-02 南京艾斯特医药科技有限公司 O-carborane derivative, and synthesis method and application thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000045857A2 (en) * 1999-02-01 2000-08-10 Schering Aktiengesellschaft Metal macrocycles for two-step forms of radiotherapy
WO2000062808A2 (en) * 1999-04-16 2000-10-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as antitumor agents
CN1524086A (en) * 2001-06-05 2004-08-25 ������������ʽ���� Process for producing methylcobalamin
CN1620289A (en) * 2001-06-06 2005-05-25 布鲁克黑文科学联合会 Novel metalloporphyrins and their uses as radiosensitizers for radiation therapy
CN101268085A (en) * 2005-08-19 2008-09-17 海默尔凯普股份公司 Boron compounds useful in BNCT
CN102977173A (en) * 2012-12-13 2013-03-20 上海华震科技有限公司 Purifying process of high-purity vitamin B12
MX2016006530A (en) * 2016-05-19 2017-11-20 Interquim S A De C V Process for transforming methylcobalamin into cyanocobalamin.
CN106279231A (en) * 2016-08-24 2017-01-04 南京江原安迪科正电子研究发展有限公司 Boron-containing compound for BNCT and its production and use
CN109928999A (en) * 2019-04-08 2019-06-25 童永彭 The preparation method and application of boron-containing compound, pharmaceutical composition and boron-containing compound
CN111217846A (en) * 2020-04-20 2020-06-02 南京艾斯特医药科技有限公司 O-carborane derivative, and synthesis method and application thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HARRY P. C. HOGENKAMP ET AL.: "Synthesis and Characterization of nido-Carborane-Cobalamin Conjugates", 《NUCLEAR MEDICINE & BIOLOGY》 *
KEITH Ó PROINSIAS T AL.: "Vitamin B12: chemical modifications", 《CHEMICAL SOCIETY REVIEWS》 *
王夔 主编: "《生命科学中的微量元素》", 31 March 1992, 中国计量出版 *

Also Published As

Publication number Publication date
CN112442095B (en) 2022-07-22

Similar Documents

Publication Publication Date Title
ES2253379T3 (en) USE OF EXTRACTS OF SpermATOFITOS AS MODULATORS OF THE IMMUNE RESPONSE.
CN101921319A (en) Rubiaceae-type cyclopeptides, medicinal compositions using same as active ingredients, and preparation method and application thereof
AU2021201778A1 (en) Novel, heavy vitamin B12 derivatives
CN109970538A (en) The Dimeric sesquiterpene compound in a kind of marine fungi source and preparation method thereof and application in preparing anti-inflammatory drugs
CN108640968B (en) Mixed-source terpenoid and application thereof in preparation of anti-inflammatory drugs
CN111410643B (en) Preparation and application of novel cinnamoyl ester catechin and four novel phenylpropanoid flavan alkaloids
CN112442095B (en) Refining method of vitamin B12 and application of obtained product
CN113908180B (en) Application of nano-selenium cordyceps militaris aqueous extract in reducing radiotherapy injury and protective agent thereof
CN108392508B (en) Application of artemisia alba extract in preparation of anti-inflammatory drugs
CN107286123B (en) Preparation method and application of diphenyl furan compound
CN102816212A (en) Rubiaceae-type cyclopeptide, its pharmaceutical composition and application
CN115636859A (en) Method for simultaneously separating and purifying two galloylated myricitrin from waxberry leaves and application
CN109081842B (en) Deep-sea fungus-derived anthraquinone compound and application thereof in preparation of antiallergic drugs
CN111499605B (en) Isopentene chromone compound and preparation method and application thereof
CN109705183B (en) Clerodendrum cyrtonema metabolite, pharmaceutical composition thereof, preparation method and application thereof
CN102051394A (en) Preparation method and application of sulfo-diketopiperazine compounds
CN112494649A (en) O-carborane compound composition for assisting BNCT
CN112661697A (en) Quaternary ammonium salt alkaloid compound in noni ferment and preparation method and application thereof
CN112480157B (en) O-carborane derivative for assisting BNCT and synthetic method thereof
CN112661779B (en) Biosynthesis method and application of N-methyl o-carborane-L-propionamide
CN115433152B (en) Compound separated from golden silk plum fruit, preparation method and application
CN109251224A (en) There is chemotherapy and the complex of iridium of phototherapy antitumor action and its preparation method and application simultaneously
CN113368090B (en) Application of 3, 4-seco cycloartenane type tetracyclic triterpene compound or pharmaceutically acceptable salt thereof in preparation of anticancer drugs
CN113582863B (en) Aminoethyl biphenyl compound and preparation method and application thereof
CN115227691B (en) Application of lactone compound from aspergillus flavus in anti-human breast cancer medicine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220630

Address after: 200000 room 131, No. 14, Lane 2165, Wangyuan Road, Fengxian District, Shanghai

Applicant after: SHANGHAI KEDAI BIO-TECH Co.,Ltd.

Address before: Room 116, building 10, Xiezhong Yaju, 618 longmian Avenue, Jiangning District, Nanjing City, Jiangsu Province

Applicant before: Nanjing Astor Pharmaceutical Technology Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant